---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026854"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:20:34.120160+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma: TXM shows positive H5N1 data in non-human primates; FDA meeting planned H1 2025

## Summary
- Single-dose TXM (480 mg) reduced lung viremia below quantitation vs up to 1x10^7 in controls after H5N1 challenge.
- TXM-treated NHPs maintained stable weight vs 4.2% loss in controls (p<0.004).
- Consistent efficacy across NHPs, ferrets (increased survival), and mice (complete survival, undetectable viremia).
- Company plans FDA meeting in H1 2025 to discuss accelerated approval under the Animal Rule.
- Investor event on March 31, 2025 at 10:00 AM ET to present TXM overview and next steps.

## SEC filing metadata
- accession: 0001104659-25-026854
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925026854/0001104659-25-026854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925026854/tm2510102d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026854
- JSON: https://secwatch.observer/filing/0001104659-25-026854.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.